Neuroendocrine evaluation of cardiac disease

Veterinary Clinics of North America - Small Animal Practice

Volumn 34, Issue 5, 2004, Pages 1105-1126

  Sisson, D David ^a  

^a Veterinary Teaching Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENOMEDULLIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ENDOTHELIN; NATRIURETIC FACTOR; NORADRENALIN; RENIN; TYROSINE; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST;

ADRENERGIC SYSTEM; AMINO ACID SEQUENCE; CARDIOVASCULAR DISEASE; CAT DISEASE; CLINICAL OBSERVATION; CONCENTRATION (PARAMETERS); CONGESTIVE HEART FAILURE; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOG DISEASE; HEMODYNAMIC PARAMETERS; HUMAN; HYPOTENSION; HYPOTHESIS; MEDICAL ASSESSMENT; NEUROENDOCRINOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREDICTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; SPECIES DIFFERENCE; VASCULARIZATION; WATER RETENTION;

ANIMALS; BLOOD CHEMICAL ANALYSIS; CAT DISEASES; CATS; DOG DISEASES; DOGS; HEART FAILURE, CONGESTIVE; PEPTIDE HORMONES; RENIN-ANGIOTENSIN SYSTEM;

ANIMALIA; CANIS FAMILIARIS; FELIDAE; FELIS CATUS;

EID: 4444243877     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2004.05.005     Document Type: Review

References (99)

1. Braunwald E. Bristow M.R. Congestive heart failure: fifty years of progress Circulation 102 2002 IV14-IV23
2. Klein L. O'Connor C.M. Gattis W.A. et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trial and practical considerations Am J Cardiol 91 Suppl 2003 18F-40F
3. Weiss M.L. Kenney M.J. Musch T.I. et al. Modifications to central neural circuitry during heart failure Acta Physiol Scand 177 2003 57-67
4. Cohn J.N. Rector T.S. Prognosis of congestive heart failure and predictors of mortality Am J Cardiol 62 1988 25A-30A
5. Kao W. Gheorghiade M. Hall V. et al. Relation between plasma norepinephrine and response to medical therapy in men with congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy Am J Cardiol 64 1989 609-613
6. Sisson D.D. Oyama M.A. Solter P.F. Plasma levels of ANP, BNP, epinephrine, norepinephrine, serum aldosterone, and plasma renin activity in healthy cats and cats with myocardial disease [abstract] J Vet Intern Med 17 2003-438
7. Ware W.A. Lund D.D. Subieta A.R. et al. Sympathetic activation in dogs with congestive heart failure caused by chronic mitral valve disease and dilated cardiomyopathy J Am Vet Med Assoc 197 1990 1475-1481
8. Lewin E.R. Gardner D.G. Samson W.K. Natriuretic peptides N Engl J Med 339 1998 321-328
9. Tamura N. Ogawa Y. Yasoda A. et al. Two cardiac natriuretic peptide genes (atrial natriuretic peptide and brain natriuretic peptide) are organized in tandem in the mouse and human genomes J Mol Cell Cardiol 28 1996 1811-1815
10. Vikstrom K.L. Bohlmeyer T. Factor S.M. et al. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis Circ Res 82 1998 773-778
11. Biondo A.W. Liu Z.L. Wiedemeyer C.E. et al. Genomic sequence and cardiac expression of atrial natriuretic peptide in cats Am J Vet Res 63 2002 236-240
12. Biondo A.W. Ehrhart E.J. Sisson D.D. et al. Immunohistochemistry of atrial and brain natriuretic peptides in control cats and cats with hypertrophic cardiomyopathy Vet Pathol 40 2003 501-506
13. Grantham J.A. Borgeson D.D. Burnett J.C. Jr. Brain natriuretic peptide: pathophysiologic and potential therapeutic roles in acute heart failure Am J Physiol 272 1997 R1077-R1083
14. Luchner A. Muders F. Dietl O. et al. Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction Cardiovasc Res 51 2001 601-607
15. Espiner E.A. Richards A.M. Yandle A.G. et al. Natriuretic hormones Endocrinol Metab Clin N Am 24 1995 481-509
16. Liu Z.L. Wiedmeyer C.E. Sisson D.D. et al. Cloning and characterization of feline brain natriuretic peptide Gene 292 2002 183-190
17. Luchner A. Stevens T.L. Borgeson D.D. et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure Am J Physiol 274 1998 H1684-H1689
18. Hasegawa K. Fujiwara H. Doyama K. et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy Circulation 88 1993 372-380
19. Dzimiri N. Moorji A. Afrane B.et al. Differential regulation of atrial and brain natriuretic peptides and its implications for the management of left ventricular volume overload Eur J Clin Invest 32 2002 563-569
20. Espiner E.A. Physiology of natriuretic peptides J Intern Med 235 1994 527-541
21. Yandle T.G. Biochemistry of natriuretic peptides J Intern Med 235 1994 561-576
22. Hunt P.J. Yandle T.G. Nicholls M.G. et al. The amino-terminal portion of pro-brain natriuretic peptide (pro-BNP) circulates in human plasma Biochem Biophys Res Commun 214 1995 1175-1183
23. Cowie M.R. Struthers A.D. Wood D.A. et al .Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care Lancet 350 1997 1349-1353
24. Haggstrom J. Hansson K. Karlberg B.E. Kvart C. Olsson K. Maeda K. Plasma concentration of atrial natriuretic peptide in relation to severity of mitral regurgitation in Cavalier King Charles Spaniels Am J Vet Res 55 5 1994 698-703
25. Tsutamoto T. Wada A. et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction Am Heart J 135 1998 825-832
26. McDonagh T.A. Robb S.D. Murdoch D.R. et al. Biochemical detection of left ventricular systolic dysfunction Lancet 351 1998 9-13
27. McCullough P.A. Nowak R.M. McCord J. et al. B-type natriuretic peptide and clinical judgment in the emergency diagnosis of heart failure: analysis from the Breathing Not Properly (BNP) Multinational Study Circulation 106 2002 416-422
28. McCullough P.A. Hollander J.E. Nowak R.M. et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department Acad Emerg Med 10 2003 198-204
29. Hammerer-Lercher A. Neubauer E. Muller S. et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction Clin Chim Acta 310 2001 193-197
30. McCullough P.A. Sandberg K.R. Sorting out the evidence on natriuretic peptides Rev Cardiovasc Med 4 Suppl 2003 S13-S19
31. McCullough P.A. Duc P. Omland T. et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study Am J Kidney Dis 41 2003 571-579
32. Haggstrom J. Hansson K. Kvart C. et al. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease J Vet Cardiol 2 2000 7-16
33. Asano K. Masuda K. Okumura M. et al. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure J Vet Med Sci 61 1999 523-529
34. MacDonald K.A. Kittleson M.D. Munro C. et al. Brain natriuretic peptide concentrations in dogs with heart disease and congestive heart failure J Vet Intern Med 17 2003 172-177
35. Tidholm A. Haggstrom J. Hansson K. Effects of dilated cardiomyopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs Am J Vet Res 62 6 2001 961-967
36. Prošek R. Sisson D. Oyama M. et al. Use of plasma ANP, BNP, endothelin-1 and troponin-I levels in distinguishing between cardiac and non-cardiac causes of acute dyspnea in dogs [abstract] J Vet Intern Med 18 2004 40
37. Nagaya N. Nishikimi T. Okano Y. et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension J Am Coll Cardiol 31 1998 202-208
38. Hasegawa K. Fujiwara H. Doyama K. et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy Circulation 88 1993 372-380
39. Yamamoto K. Burnett J.C. Jr. Jougasaki M. et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and left ventricular hypertrophy Hypertension 28 1996 988-994
40. Wallen T. Landahl S. Hedner T. et al. Brain natriuretic peptide predicts mortality in the elderly Heart 77 1997 264-267
41. Tsutamoto T. Atsuyuki W. Maeda K. et al. Attenuation of compensation of endogenous natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction Circulation 96 1997 509-516
42. Maeda K. Tsutamoto T. Wada A. et al. High level of plasma BNP at discharge is an independent risk factor for mortality and morbidity in patients with congestive heart failure J Am Coll Cardiol 192A 1999 1113-1140
43. Troughton R.W. Frampton C.M. Yandle T.G. et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126-1130
44. Griendling K.K. Murphy T.J. Alexander R.W. Molecular biology of the renin-angiotensin system Circulation 87 1993 1817-1828
45. Kotchen T.A. Roy M.W. Renin-angiotensin In: Dunn M.J. editor, Renal endocrinology 1983 181-204 Williams & Wilkins Baltimore
46. Weber K.T. Aldosterone in congestive heart failure N Engl J Med 345 2001 1689-1697
47. Hollenberg N.K. Implications for species difference for clinical investigation. Studies on the renin-angiotensin system Hypertension 35 2000 150-154
48. Song J.C. White C.M. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists Pharmacotherapy 20 2000 130-139
49. Cha A.J. Malecha S.E. Judge K.W. Aldosterone, a new appreciation of its role in heart failure Pharmacotherapy 20 2000 1107-1115
50. Rocha R. Funder J.W. The pathophysiology of aldosterone in the cardiovascular system Ann NY Acad Sci 970 2002 89-100
51. Beneteau-Burnat B. Baudin B. Angiotensin-converting enzyme: clinical applications and laboratory investigations on serum and other biological fluids Crit Rev Clin Lab Sci 28 1991 337-356
52. Burnier M. Waeber B. Nussberger J. et al. Pharmacokinetics of angiotensin converting enzyme inhibitors Br J Clin Pharmacol 28 Suppl 2 1989 133S-139S
53. Belz G.G. Kirch W. Kleinbloesem C.H. Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics Clin Pharmacokinet 15 1988 295-318
54. Schalekamp M.A. Derkx F.H. van der Meiracker A.H. Renin inhibitors, angiotensin converting enzyme inhibitors, and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system Hypertens Suppl 10 1992 10S157-14
55. Hamlin R.L. Nakayama T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles J Vet Intern Med 12 1998 93-95
56. King J.N. Maurer M. Morrison M. et al. Pharmacokinetics of the angiotensin-converting-enzyme, benazepril, and its active metabolite, benazeprilat, in dog Xenobiotica 27 1997 819-829
57. King J.N. Humbert-Droz E. Maurer M. Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril HCl J Vet Pharmacol Ther 22 1999 360-367
58. King J.N. Maurer M. Toutain P.L. Pharmacokinetic/pharmacodynamic modeling of the disposition and effect of benazepril and benazeprilat in cats J Vet Pharmacol Ther 26 2003 213-224
59. Nussberger J. Waeber B. Brunner H.R. Plasma angiotensin II and the antihypertensive action of angiotensin-converting enzyme inhibition Am J Hypertens 2 1989 286-293
60. Juillerat L. Nussberger J. Menard J. et al. Determinants of angiotensin II generation during converting enzyme inhibition Hypertension 16 1990 564-572
61. Lacher N.A. Garrison K.E. Lunte S.M. Separation and detection of angiotensin peptides by CU(II) complexation and capillary electrophoresis with UV and electrochemical detection Electrophoresis 23 2002 1577-1584
62. Paulson S. Verhage L. Mayer D. et al. A nonequilibrium radioimmunoassay for angiotensin II J Pharmacol Toxicol Methods 32 1994 93-97
63. Cunningham S.K. Sequeira S.J. Chambers J. et al. Optimisation of total urinary aldosterone estimation: comparison with other laboratory methods for assessment of mineralocorticoid status J Steroid Biochem 31 1988 125-130
64. Francis G.S. Neuroendocrine activity in congestive heart failure Am J Cardiol 66 1990 33D-39D
65. Haggstrom J. Hansson K. Karlberg B.E. et al. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation Am J Vet Res 57 1996 1645-1652
66. Knowlen G.G. Kittleson M.D. Nachreiner R.F. et al. Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure J Am Vet Med Assoc 183 1983 991-996
67. Koch J. Pedersen H.D. Jensen A.L. et al. Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathy Res Vet Sci 59 1995 172-175
68. Haggstrom J. Hansson K. Kvart C. et al. Am J Vet Res Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs 58 1997 77-82
69. Pedersen H.D. Koch J. Poulsen K. et al. Activation of the renin-angiotensin system in dogs with asymptomatic and mildly symptomatic mitral valvular insufficiency J Vet Intern Med 9 1995 328-331
70. Pedersen H.D. Effects of mild mitral valve insufficiency, sodium intake, and place of blood sampling on the renin-angiotensin system in dogs Acta Vet Scand 37 1996 109-118
71. Hayne W.G. Webb D.J. Endothelin as a regulator of cardiovascular function in health and disease J Hypertens 16 1998 1081-1098
72. Pearson J.D. Normal endothelial cell function Lupus 9 2000 183-188
73. Inoue A. Yanagisawa M. Kimura S. et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes Proc Natl Acad Sci USA 26 1989 2863-2867
74. Miyauchi T. Masaki T. Pathophysiology of endothelin in the cardiovascular system Annu Rev Physio 61 1999 391-415
75. Hocher B. Thöne-Reineke C. Bauer C. et al. The paracrine endothelin system: pathophysiology and implications in clinical medicine Eur J Clin Chem Clin Biochem 35 1997 175-179
76. Noll G. Wenzell R.R. Lüscher T.F. Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease Mol Cell Biochem 157 1996 259-267
77. Rossi G.P. Sacchhetto A. Cesari et al. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system Cardiovasc Res 43 1999 300-307
78. Rodeheffer R.J. Lerman A. Heublin D.M. et al. Concentrations of endothelin in congestive heart failure in humans Mayo Clin Proc 67 1992 719-724
79. Wei C.M. Lerman A. Rodeheffer R.J. et al. Endothelin in human congestive heart failure Circulation 89 1994 1580-1586
80. Rubens C. Ewert R. Halank M. et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension Chest 120 2001 1562-1569
81. Biondo A.W. Wiedmeyer C.E. Sisson D.D. Solter P.F. Comparative sequences of canine and feline endothelin-1 Vet Clin Pathol 32 2003 188-194
82. Prošek R. Sisson D.D. Oyama M.A. et al. Measurements of plasma endothelin immunoreactivity in healthy cats and cats with cardiomyopathy. J Vet Intern Med, in press
83. Prošek R. Sisson D.D. Oyama M.A. et al. Plasma endothelin-1 concentrations in healthy dogs and dogs with acquired heart disease. J Vet Intern Med, in press.
84. Pacher R. Bergler-Klein J. Globis S. et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension Am J Cardiol 71 1993 1293-1299
85. Loffler B.M. Endothelin-converting enzyme inhibitors: current status and perspectives J Cardiovasc Pharmacol 35 4 Suppl 3 2000 S79-S82
86. Lee C.R. Watkins M.L. Patterson J.H. et al. Vasopressin: a new target for the treatment of heart failure Am Heart J 146 2003 9-18
87. Schrier R.W. Abraham W. Hormones and hemodynamics in heart failure N Engl J Med 341 1999 577-585
88. Biondo A.W. Souza C. Sisson D.D. et al. Felis catus arginine-vasopressin precursor, mRNA, partial cds Accession AF406782 NCBI 2003
89. Wong L.L. Verbalis J.G. Vasopressin V2 receptor antagonists Cardiovasc Res 51 2001 391-402
90. 2 receptor antagonists J Mol Endocrinol 29 2002 1-9
91. Goldsmith S.R. Francis G.S. Cowley E.W. et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure J Am Coll Cardiol 1 1983 1385-1390
92. Gheorghiade M. Orlandi C. Gottlieb S. ET AL. Vasopressin V2 receptor blockade versus fluid restriction in the treatment of hyponatremia: results from a multicenter randomized clinical trial [abstract] J Am Coll Cardiol 39 5 Suppl 2002-438
93. Gross P. Palm C. The treatment of hyponatremia using vasopressin antagonists Exp Pharmacol 85 Suppl 2000 253S-257S
94. 2 vasopressin receptor antagonist, in patients with advanced heart failure Circulation 104 2001 2417-2423
95. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure Eur J Pharmacol 376 1999 239-246
96. Jougasaki M. Burnett J.C. Adrenomedullin: potential in physiology and pathophysiology Life Sci 66 2000 855-872
97. Jougasaki M. Grantham J.A. Redfield M.M. et al. Regulation of cardiac adrenomedullin in heart failure Peptides 22 2001 1841-1850
98. Jougasaki M. Wei C.-M. McKinley L.J. et al. Elevation of circulating, and ventricular adrenomedullin in human congestive heart failure Circulation 92 1995 286-289
99. Kato J. Kobayashi K. Etoh T. et al. Plasma adrenomedullin concentrations in patients with heart failure J Clin Endocrinol Metab 81 1996 180-183